SLC5A11

Summary

SLC5A11 (solute carrier family 5 member 11, HGNC:23091) is a protein-coding gene on chromosome 16p12.1, encoding Sodium/myo-inositol cotransporter 2 (Q8WWX8). Involved in the sodium-dependent cotransport of myo-inositol (MI) with a Na(+):MI stoichiometry of 2:1.

Cotransporters, such as SLC5A11, represent a major class of proteins that make use of ion gradients to drive active transport for the cellular accumulation of nutrients, neurotransmitters, osmolytes, and ions Roll et al. (2002) [PubMed 12039040].

Source: NCBI Gene 115584 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 95 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_001352248

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23091
Approved symbol	SLC5A11
Name	solute carrier family 5 member 11
Location	16p12.1
Locus type	gene with protein product
Status	Approved
Aliases	KST1, SMIT2, SGLT6
Ensembl gene	ENSG00000158865
Ensembl biotype	protein_coding
OMIM	610238
Entrez	115584

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 10 protein_coding, 2 nonsense_mediated_decay, 2 retained_intron

ENST00000347898, ENST00000424767, ENST00000488922, ENST00000545376, ENST00000564125, ENST00000565586, ENST00000565769, ENST00000567758, ENST00000568579, ENST00000569071, ENST00000569520, ENST00000899689, ENST00000899690, ENST00000960822

RefSeq mRNA: 21 — MANE Select: NM_001352248 NM_001258411, NM_001258412, NM_001258413, NM_001258414, NM_001352235, NM_001352236, NM_001352237, NM_001352238, NM_001352242, NM_001352245, NM_001352246, NM_001352247, NM_001352248, NM_001352249, NM_001352250, NM_001352259, NM_001394076, NM_001394077, NM_001394078, NM_001394079, NM_001394080

CCDS: CCDS10625, CCDS58437, CCDS58438, CCDS58439, CCDS58440

Canonical transcript exons

ENST00000424767 — 17 exons

Exon	Start	End
ENSE00001350758	24846232	24846438
ENSE00002677296	24858620	24858778
ENSE00003467842	24884051	24884131
ENSE00003472245	24907025	24907175
ENSE00003485012	24906657	24906764
ENSE00003489375	24908881	24909096
ENSE00003538918	24875627	24875731
ENSE00003553874	24872160	24872219
ENSE00003559653	24862601	24862672
ENSE00003621329	24869901	24870005
ENSE00003626069	24907963	24908131
ENSE00003671985	24897974	24898109
ENSE00003681736	24910306	24910477
ENSE00003687009	24890869	24891074
ENSE00003694405	24877258	24877363
ENSE00003924311	24845963	24846012
ENSE00003938135	24911328	24911626

Expression profiles

Bgee: expression breadth ubiquitous, 125 present calls, max score 97.31.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.4184 / max 379.9191, expressed in 81 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
153258	0.7658	69
153257	0.5121	68
153259	0.0828	44
153260	0.0577	25

Top tissues by expression

131 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
C1 segment of cervical spinal cord	UBERON:0006469	97.31	gold quality
corpus callosum	UBERON:0002336	95.60	gold quality
substantia nigra	UBERON:0002038	93.89	gold quality
primary visual cortex	UBERON:0002436	89.64	gold quality
Ammon’s horn	UBERON:0001954	88.20	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.64	gold quality
Brodmann (1909) area 9	UBERON:0013540	83.42	gold quality
hypothalamus	UBERON:0001898	82.19	gold quality
putamen	UBERON:0001874	80.34	gold quality
temporal lobe	UBERON:0001871	79.39	gold quality
amygdala	UBERON:0001876	79.23	gold quality
superior frontal gyrus	UBERON:0002661	79.14	gold quality
cerebral cortex	UBERON:0000956	78.66	gold quality
frontal cortex	UBERON:0001870	78.53	gold quality
duodenum	UBERON:0002114	78.49	gold quality
prefrontal cortex	UBERON:0000451	78.42	gold quality
right frontal lobe	UBERON:0002810	78.05	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	77.70	gold quality
brain	UBERON:0000955	74.72	gold quality
anterior cingulate cortex	UBERON:0009835	74.42	gold quality
right hemisphere of cerebellum	UBERON:0014890	73.31	gold quality
small intestine Peyer’s patch	UBERON:0003454	73.25	gold quality
small intestine	UBERON:0002108	72.95	gold quality
caudate nucleus	UBERON:0001873	71.30	gold quality
cerebellum	UBERON:0002037	70.87	gold quality
cerebellar cortex	UBERON:0002129	70.76	gold quality
cerebellar hemisphere	UBERON:0002245	70.69	gold quality
adult mammalian kidney	UBERON:0000082	69.31	gold quality
nucleus accumbens	UBERON:0001882	69.00	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	65.32	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	1153.66
E-HCAD-25	yes	71.01
E-ANND-3	yes	3.73

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 1)

• SLC5A11 is involved with some immune effects and interacts with immune-related gene(s); it is consistent with its function as an autoimmune modifier gene. (PMID:18069935)

Cross-species orthologs

13 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc5a11	ENSDARG00000019932
mus_musculus	Slc5a11	ENSMUSG00000030769
rattus_norvegicus	Slc5a11	ENSRNOG00000013407
drosophila_melanogaster	CG2187	FBGN0017448
drosophila_melanogaster	rumpel	FBGN0029950
drosophila_melanogaster	SLC5A11	FBGN0031998
drosophila_melanogaster	bumpel	FBGN0037895
drosophila_melanogaster	salt	FBGN0039872
drosophila_melanogaster	Smvt	FBGN0039873
drosophila_melanogaster	CG31262	FBGN0051262
drosophila_melanogaster	CG31668	FBGN0051668
drosophila_melanogaster	CG33124	FBGN0053124
drosophila_melanogaster	kumpel	FBGN0250757

Paralogs (12): SLC5A1 (ENSG00000100170), SLC5A4 (ENSG00000100191), SLC5A5 (ENSG00000105641), SLC5A7 (ENSG00000115665), SLC5A9 (ENSG00000117834), SLC5A6 (ENSG00000138074), SLC5A2 (ENSG00000140675), SLC5A12 (ENSG00000148942), SLC5A10 (ENSG00000154025), SLC5A3 (ENSG00000198743), SLC5A8 (ENSG00000256870), (ENSG00000293606)

Protein

Protein identifiers

Sodium/myo-inositol cotransporter 2 — Q8WWX8 (reviewed: Q8WWX8)

Alternative names: Sodium-dependent glucose cotransporter, Sodium/glucose cotransporter KST1, Sodium/myo-inositol transporter 2, Solute carrier family 5 member 11

All UniProt accessions (4): Q8WWX8, A0A8J9ASH1, H3BN85, I3L1G0

UniProt curated annotations — full annotation on UniProt →

Function. Involved in the sodium-dependent cotransport of myo-inositol (MI) with a Na(+):MI stoichiometry of 2:1. Exclusively responsible for apical MI transport and absorption in intestine. Can also transport D-chiro-inositol (DCI) but not L-fucose. Exhibits stereospecific cotransport of both D-glucose and D-xylose. May induce apoptosis through the TNF, PDCD1 pathway. May play a role in the regulation of MI concentration in serum, involving reabsorption in at least the proximal tubule of the kidney.

Subcellular location. Membrane. Apical cell membrane.

Tissue specificity. Highest expression in heart, skeletal muscle, kidney, liver and placenta. Weaker expression in brain, colon, spleen, lung and peripheral blood leukocytes.

Activity regulation. MI transport activity inhibited by D-chiro-inositol (DCI), phlorizin (Pz) and sodium (Na(+)). Insulin increases D-chiro-inositol uptake.

Miscellaneous. Acts as an autoimmune modifier in systemic lupus erythematosus (SLE) as it is significantly associated with low complement component 4 (C4), anti-Smith antibody, serositis, and alopecia.

Similarity. Belongs to the sodium:solute symporter (SSF) (TC 2.A.21) family.

Isoforms (6)

UniProt ID	Names	Canonical?
Q8WWX8-1	1	yes
Q8WWX8-2	2
Q8WWX8-3	3
Q8WWX8-4	4
Q8WWX8-5	5
Q8WWX8-6	6

RefSeq proteins (21): NP_001245340, NP_001245341, NP_001245342, NP_001245343, NP_001339164, NP_001339165, NP_001339166, NP_001339167, NP_001339171, NP_001339174, NP_001339175, NP_001339176, NP_001339177, NP_001339178, NP_001339179, NP_001339188, NP_001381005, NP_001381006, NP_001381007, NP_001381008, NP_001381009 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001734	Na/solute_symporter	Family
IPR038377	Na/Glc_symporter_sf	Homologous_superfamily

Pfam: PF00474

Catalyzed reactions (Rhea), 4 shown:

• D-glucose(out) + 2 Na(+)(out) = D-glucose(in) + 2 Na(+)(in) (RHEA:70495)
• myo-inositol(out) + 2 Na(+)(out) = myo-inositol(in) + 2 Na(+)(in) (RHEA:72987)
• 1D-chiro-inositol(out) + 2 Na(+)(out) = 1D-chiro-inositol(in) + 2 Na(+)(in) (RHEA:73315)
• D-xylose(out) + 2 Na(+)(out) = D-xylose(in) + 2 Na(+)(in) (RHEA:73367)

UniProt features (44 total): topological domain 14, transmembrane region 14, splice variant 6, sequence variant 6, sequence conflict 3, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WWX8-F1	82.19	0.48

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-429593	Inositol transporters
R-HSA-382551	Transport of small molecules
R-HSA-425366
R-HSA-425407	SLC-mediated transmembrane transport

MSigDB gene sets: 63 (showing top): GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_ORGANIC_HYDROXY_COMPOUND_TRANSPORT, GOBP_POLYOL_TRANSMEMBRANE_TRANSPORT, BALLIF_DEVELOPMENTAL_DISABILITY_P16_P12_DELETION, SANSOM_APC_TARGETS_DN, GOCC_APICAL_PLASMA_MEMBRANE, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, GOBP_TRANSMEMBRANE_TRANSPORT, GOBP_SODIUM_ION_TRANSPORT, GOCC_APICAL_PART_OF_CELL, chr16p12, GOCC_PLASMA_MEMBRANE_REGION, GOMF_ACTIVE_TRANSMEMBRANE_TRANSPORTER_ACTIVITY, GOMF_SECONDARY_ACTIVE_TRANSMEMBRANE_TRANSPORTER_ACTIVITY, GOMF_POLYOL_TRANSMEMBRANE_TRANSPORTER_ACTIVITY

GO Biological Process (9): apoptotic process (GO:0006915), myo-inositol transport (GO:0015798), monoatomic ion transport (GO:0006811), sodium ion transport (GO:0006814), hexose transmembrane transport (GO:0008645), polyol transmembrane transport (GO:0015791), carbohydrate transmembrane transport (GO:0034219), sodium ion transmembrane transport (GO:0035725), transmembrane transport (GO:0055085)

GO Molecular Function (6): myo-inositol transmembrane transporter activity (GO:0005365), D-glucose:sodium symporter activity (GO:0005412), polyol transmembrane transporter activity (GO:0015166), protein binding (GO:0005515), symporter activity (GO:0015293), transmembrane transporter activity (GO:0022857)

GO Cellular Component (3): plasma membrane (GO:0005886), apical plasma membrane (GO:0016324), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
SLC-mediated transmembrane transport	1
Transport of small molecules	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transmembrane transport	3
organic hydroxy compound transport	2
transport	2
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
metal ion transport	1
monosaccharide transmembrane transport	1
carbohydrate transport	1
sodium ion transport	1
monoatomic cation transmembrane transport	1
cellular process	1
polyol transmembrane transporter activity	1
myo-inositol transport	1
carbohydrate:monoatomic cation symporter activity	1
solute:sodium symporter activity	1
D-glucose transmembrane transporter activity	1
polyol transmembrane transport	1
transmembrane transporter activity	1
binding	1
secondary active transmembrane transporter activity	1
transporter activity	1
membrane	1
cell periphery	1
apical part of cell	1
plasma membrane region	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1047 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC5A11	SLC2A2	P11168	628
SLC5A11	SLC2A13	Q96QE2	593
SLC5A11	SLC2A5	P22732	556
SLC5A11	SLC2A12	Q8TD20	480
SLC5A11	SLC2A1	P11166	473
SLC5A11	SLC13A4	Q9UKG4	433
SLC5A11	SLC2A8	Q9NY64	427
SLC5A11	H7C1H1	H7C1H1	408
SLC5A11	MGAM	O43451	399
SLC5A11	SI	P14410	392
SLC5A11	SLC2A3	P11169	385
SLC5A11	SLC2A11	Q9BYW1	385
SLC5A11	SLC2A4	P14672	379
SLC5A11	SLC15A1	P46059	379
SLC5A11	GCG	P01275	375

IntAct

8 interactions, top by confidence:

A	B	Type	Score
KPNA3	SLC5A11	psi-mi:“MI:0915”(physical association)	0.560
SLC5A11	KPNA3	psi-mi:“MI:0915”(physical association)	0.560
SLC5A11	SPTAN1	psi-mi:“MI:0915”(physical association)	0.400
SLC5A11	LINGO1	psi-mi:“MI:0914”(association)	0.350
KLHL22	TRAV18	psi-mi:“MI:0914”(association)	0.350
SLC5A12	PLPP3	psi-mi:“MI:0914”(association)	0.350

BioGRID (10): SLC5A11 (Two-hybrid), KPNA3 (Two-hybrid), LINGO1 (Affinity Capture-MS), SLC5A11 (Proximity Label-MS), SLC5A11 (Affinity Capture-MS), LINGO1 (Affinity Capture-MS), CBLN4 (Affinity Capture-MS), SLC5A11 (Positive Genetic), SLC5A11 (Affinity Capture-MS), SLC5A11 (Affinity Capture-MS)

ESM2 similar proteins: A0PJK1, A8I1B9, A8WHP3, B9NAE4, D3ZIS0, O02228, O77741, P11170, P13866, P26429, P26430, P31636, P31637, P31639, P41251, P49279, P49280, P53790, P53791, P53792, P53793, P53794, P56436, P70553, P83740, Q27946, Q27981, Q28610, Q28728, Q2M3M2, Q3ZC26, Q5FY69, Q5SWY8, Q6R4Q5, Q7T384, Q8BGY9, Q8C3K6, Q8K0E3, Q8UWF0, Q8VDT1

Diamond homologs: A0PJK1, A8I1B9, A8WHP3, D3ZIS0, P11170, P13866, P26429, P26430, P31636, P31637, P31639, P53790, P53791, P53792, P53793, P53794, P96169, Q28610, Q28728, Q2M3M2, Q3ZC26, Q5FY69, Q5SWY8, Q6R4Q5, Q8C3K6, Q8K0E3, Q8VDT1, Q8WWX8, Q91ZP4, Q923I7, Q9ET37, Q9JKZ2, Q9NY91, Q9Z1F2, P31448

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

95 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	81
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2701 predictions. Top by Δscore:

Variant	Effect	Δscore
16:24861971:T:A	acceptor_gain	1.0000
16:24862599:A:AG	acceptor_gain	1.0000
16:24862600:G:GA	acceptor_gain	1.0000
16:24862668:GGCCA:G	donor_gain	1.0000
16:24862669:GCCAG:G	donor_gain	1.0000
16:24862673:G:GG	donor_gain	1.0000
16:24869895:CCACA:C	acceptor_loss	1.0000
16:24869896:CACA:C	acceptor_loss	1.0000
16:24869897:ACAGG:A	acceptor_loss	1.0000
16:24869898:CA:C	acceptor_loss	1.0000
16:24869899:A:C	acceptor_loss	1.0000
16:24869900:G:C	acceptor_loss	1.0000
16:24870006:G:GG	donor_gain	1.0000
16:24875728:CTCGG:C	donor_loss	1.0000
16:24875729:TCGG:T	donor_loss	1.0000
16:24875732:G:GG	donor_gain	1.0000
16:24875733:T:G	donor_loss	1.0000
16:24884132:G:GG	donor_gain	1.0000
16:24897970:CCAG:C	acceptor_loss	1.0000
16:24897972:A:AG	acceptor_gain	1.0000
16:24897972:A:T	acceptor_loss	1.0000
16:24897972:AG:A	acceptor_gain	1.0000
16:24897972:AGGT:A	acceptor_gain	1.0000
16:24897973:G:GG	acceptor_gain	1.0000
16:24897973:G:GT	acceptor_loss	1.0000
16:24897973:GG:G	acceptor_gain	1.0000
16:24897973:GGT:G	acceptor_gain	1.0000
16:24897973:GGTG:G	acceptor_gain	1.0000
16:24897973:GGTGA:G	acceptor_gain	1.0000
16:24898106:CCAG:C	donor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000008443 (16:24862460 C>A), RS1000050412 (16:24886466 TTC>T), RS1000080609 (16:24901912 C>T), RS1000093050 (16:24891567 T>A), RS1000124796 (16:24903642 T>C), RS1000261917 (16:24880675 C>T), RS1000280890 (16:24883894 G>A), RS1000331901 (16:24895909 G>A), RS1000377250 (16:24896216 T>C), RS1000441963 (16:24889566 T>C), RS1000489267 (16:24904072 C>T), RS1000493646 (16:24845394 T>C), RS1000506004 (16:24857941 G>A), RS1000536957 (16:24857591 G>A), RS1000607202 (16:24851666 C>T)

Disease associations

OMIM: gene MIM:610238 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST002479_14	Lupus nephritis in systemic lupus erythematosus	5.000000e-07
GCST003119_20	Urinary metabolites	9.000000e-66
GCST006979_653	Heel bone mineral density	6.000000e-10
GCST007611_6	Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)	1.000000e-08
GCST009733_45	Urinary metabolite levels in chronic kidney disease	7.000000e-30
GCST010703_260	Brain morphology (MOSTest)	2.000000e-13

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0005116	urinary metabolite measurement
EFO:0009270	heel bone mineral density
EFO:0004346	neuroimaging measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1744524 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 5,323 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL429910	DAPAGLIFLOZIN	4	5,323

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — Sodium myo-inositol cotransporter transporters

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
phlorizin	Inhibition	4.1	pKi

ChEMBL bioactivities

2 potent at pChembl≥5 of 3 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.42	IC50	380	nM	DAPAGLIFLOZIN
5.04	IC50	9200	nM	CHEMBL1762505

PubChem BioAssay actives

2 with measured affinity, of 4 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
Dapagliflozin	589976: Inhibition of SGLT6 expressed in CHO cells assessed as inhibition of [14C]-alpha-methyl-D-glucopyranoside transport after 60 mins by scintillation counting	ic50	0.3800	uM
6,8-dichloro-4-[[5-[2-(4-chlorophenyl)ethyl]-4-(3,3,3-trifluoropropyl)-1,2,4-triazol-3-yl]methyl]-1,4-benzoxazin-3-one	589976: Inhibition of SGLT6 expressed in CHO cells assessed as inhibition of [14C]-alpha-methyl-D-glucopyranoside transport after 60 mins by scintillation counting	ic50	9.2000	uM

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases expression	4
sodium arsenite	affects methylation, increases expression	2
aristolochic acid I	increases expression	1
methyleugenol	increases expression	1
propionaldehyde	decreases expression	1
bisphenol A	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
butyraldehyde	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment	1
pentanal	decreases expression	1
CGP 52608	affects binding, increases reaction	1
abrine	decreases expression	1
(+)-JQ1 compound	decreases expression	1
Aldehydes	decreases expression	1
Lipopolysaccharides	affects response to substance, increases expression, affects cotreatment	1
N-Nitrosopyrrolidine	increases expression	1
Phenobarbital	increases expression	1
Rifampin	increases expression	1
Silicon Dioxide	decreases expression	1
Thiram	increases expression	1
Triclosan	increases expression	1
Urethane	decreases expression	1
2,4-Dichlorophenoxyacetic Acid	decreases expression	1
Aflatoxin B1	decreases expression	1
Okadaic Acid	increases expression	1
Copper Sulfate	increases expression	1

ChEMBL screening assays

2 unique, capped per target: 1 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1763187	Binding	Inhibition of SGLT6 expressed in CHO cells assessed as inhibition of [14C]-alpha-methyl-D-glucopyranoside transport after 60 mins by scintillation counting	Discovery of non-glucoside SGLT2 inhibitors. — Bioorg Med Chem Lett
CHEMBL5209619	Functional	Substrate uptake by the Sodium/myo-inositol cotransporter 2 (SMIT2, SLC5A11) as assessed by the fluorescent FLIPR membrane potential dye in HEK-293 JumpIN-SLC5A11 cells (PubChem AID: 1794826)	Membrane potential based assay for SLC5A11 using HEK-293 SLC5A11 OE cells

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.